吸入舒利迭与辅舒酮防治慢性阻塞性肺病的对比观察

The clinical effect observation of inhaling seretide and flixotide treatment chronic obstructive pulmonary disease(COPD)

目的对比观察吸入舒利迭(丙酸氟替卡松/沙美特罗)与辅舒酮(氟替卡松)对慢性阻塞性肺病(COPD)的疗效。方法204例COPD患者随机分为治疗组和对照组各102例,治疗组吸入舒利迭,对照组吸入辅舒酮,观察2组临床疗效和肺功能改善情况。结果治疗组治疗后肺功能明显改善(P<0.05),治疗组总有效率为91.2%高于对照组的74.5%,差异有统计学意义(P<0.05),使用β2受体激动剂次数和因急性发作住院次数少于对照组(P<0.01)。结论吸入舒利达防治COPD疗效显著。

Objective To observe the clinical value of in haling seretide and flixotide in chronic obstructive pulmonary disease（COPD）. Methods 204 cases of COPD patients were randomly divided into treatment group and control group, 102 cases of each. The patients in control group inhaled flixotide, and the treatment group inhaled seretide. The comparison was made on the clinical value and Lung function. Results Compared with those before treatment, lung＇function of the treatment group improved significanntly after treatment（ P 〈 0.05 ） ;With total effictive rate 91.2% higher than 74. 5% of control group （P 〈 0.05 ） ,the frequency of use β2 agonist and hospitalization due to alute exacerbation were less than the control group（ P 〈 0.01 ）. Conclusion Inhalation of seretide prevention and treatment of chronic obstructive pulmonary disease is significant effect.